Multi-Cancer Blood Tests Face the FDA With a Trial That Missed Its Own Primary Endpoint

What the NHS Trial Actually Found

NHS-Galleri randomized 142,000 asymptomatic adults aged 50 to 77 to either standard NHS cancer screening alone or standard screening plus an annual Galleri blood draw, followed for three years. Its primary endpoint was a statistically significant reduction in cancers diagnosed at stage III or IV, the stages associated with the worst outcomes. That endpoint was not met. GRAIL's own chief executive, Bob Ragusa, said as much in the results release: "the primary endpoint of statistically significant Stage III-IV reduction was not observed," though he pointed to "a favorable trend toward fewer Stage III-IV cancers." The secondary findings were more favorable to the test: a four-fold higher overall cancer detection rate in the group screened with Galleri, a substantial increase in stage I and II detection of the deadliest cancer types, and, in the trial's second and third screening rounds specifically, a reduction of more than 20% in those same twelve high-mortality cancers presenting at stage IV.

Oncologists reviewing the release were careful not to conflate the secondary signal with proof. Dr. Nima Nabavizadeh called the primary endpoint miss "an important thing that's taken seriously," and Dr. Elizabeth O'Donnell noted that "what the press release offers is very limited, there is still a lot to be learned," pointing to the full data presentation scheduled for the ASCO Annual Meeting in late May 2026 as the point at which the trial can actually be assessed in detail. University College London's Professor Charles Swanton framed the clinical stakes plainly: catching cancer before it spreads allows treatment aimed at cure, while metastatic disease usually means a shift to long-term disease control rather than cure. No serious safety concerns were reported among trial participants.

Source: GRAIL press releases, January 29, 2026 and February 19, 2026; Lung Cancer Today, expert reaction coverage.

The Argument That Matters More Than Sensitivity

Critics of multi-cancer testing have generally focused on a real weakness: Galleri's sensitivity across all cancer types in PATHFINDER 2 was only 40.4%, rising to 73.7% for the twelve cancers that cause two-thirds of U.S. cancer deaths, meaning the test misses a meaningful share of cancers outright. But a 2025 peer-reviewed modeling study in a PMC-indexed journal makes a different, and in some ways more interesting, argument: the comparison that matters is not multi-cancer testing against a perfect test, it is multi-cancer testing against the realistic alternative of running ten separate single-cancer tests to try to cover the same ground. Modeling both approaches across 100,000 adults aged 50 to 79, the study found the ten-test panel would generate 93,289 diagnostic workups in people who turned out not to have cancer, versus 497 for the single multi-cancer test, at a false-positive workup cost of roughly $242.7 million against $2.2 million. The ten-test panel did find more cancers, 412 versus 298, but at the cost of 188 times more unnecessary invasive follow-up in people who were never sick.

That tradeoff is the real regulatory and clinical question, and it is a harder one than either side's marketing suggests. A test that finds fewer cancers but avoids tens of thousands of unnecessary biopsies and scans is not obviously worse medicine, but it is also not the same claim as "detects cancer early," and the two get blurred constantly in how these tests are discussed publicly.

What the FDA Panel Is Actually Deciding

The September 23 advisory committee meeting is not a vote on whether Galleri works in some general sense, it is a vote on a specific premarket approval application built substantially on PATHFINDER 2's performance data, with NHS-Galleri offered as supporting, not primary, evidence. GRAIL President Josh Ofman has framed the regulatory case around addition rather than replacement, saying "adding Galleri to standard screening tests has potential to dramatically improve performance of the nation's screening program," language that positions the test as a supplement to mammography, colonoscopy, and low-dose CT rather than a substitute for any of them. A Breakthrough Device designation, which Galleri has held since 2018, speeds FDA interaction but does not lower the evidentiary bar for approval itself. Whether the panel treats the NHS-Galleri endpoint miss as disqualifying or as an acceptable tradeoff against the detection-rate and false-positive data will likely set the template other multi-cancer developers, several of them well funded and watching this decision closely, will need to follow.

Full NHS-Galleri data lands at ASCO in late May 2026. The FDA panel convenes four months before that fuller picture is public, on the strength of a results release that two of the oncologists who reviewed it called incomplete. Whichever way the panel leans, this is a decision being made in the middle of the evidence, not after it.

This piece covers clinical and regulatory developments only. Market sizing and forecasts for the Multi-Cancer Early Detection Market are covered in the companion Vectomat Insights RDPR report.

Sources

1. CLP Magazine. "FDA Advisory Committee to Review GRAIL Multi-Cancer Early Detection Test." clpmag.com.

2. GRAIL. "GRAIL Submits FDA Premarket Approval Application for the Galleri Multi-Cancer Early Detection Test." Press release, January 29, 2026. grail.com.

3. GRAIL. "Landmark NHS-Galleri Trial Demonstrates a Substantial Reduction in Stage IV Cancer Diagnoses, Increased Stage I and II Detection of Deadly Cancers, and Four-Fold Higher Cancer Detection Rate." Press release, February 19, 2026. grail.com.

4. GRAIL. "GRAIL PATHFINDER 2 Results Show Galleri Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings." grail.com.

5. Lung Cancer Today. "NHS-Galleri Trial of Multi-Cancer Early Detection Test Fails to Meet Primary Endpoint: Experts React." lungcancerstoday.com.

6. PMC (National Library of Medicine). "Estimating the Burden of False Positives and Implementation Costs From Adding Multiple Single Cancer Tests or a Single Multi-Cancer Test to Standard-of-Care Screening." pmc.ncbi.nlm.nih.gov/articles/PMC11912434.

7. MedTech Dive. "Grail files for FDA approval of multi-cancer early detection test." medtechdive.com.

Vectomat Insights is an independent healthcare and life sciences market intelligence practice. This article is editorial analysis prepared by the Vectomat Insights Research Desk from publicly available sources cited above and does not constitute investment, medical, or regulatory advice.